Familial benign chronic pemphigus or Haily-Haily disease
Conditions
Interventions
Experimental group and control group:Type A botulinum toxin injection
control group:Traditional topical medication treatment
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.The participant shall sign the informed consent, commit to adhering to the research procedures, and actively cooperate with the complete implementation of the research process. 2.The clinical presentation and histopathological diagnosis of Hailey-Hailey disease are necessary for patients who are 18 years old and above. 3.In order to ensure the accuracy of screening results, it is recommended that fertile women use contraception for a minimum duration of one month prior to screening and commit to its consistent use throughout the study period, as well as until the specified time after completion of the study. 4.The trial was conducted without the administration of any drugs or treatments that could potentially influence the outcomes. 5.Refrain from participating in any other clinical trials at different research centers throughout the duration of the trial.
Exclusion criteria
Exclusion criteria: 1.The patients who were not able to be followed up with. 2.The patient should not receive Botox-A or its excipients if they have a documented allergy, myotonia, dysphagia, a history of dysphagia, or a previous episode of aspiration pneumonia. 3.Patients suffering from severe systemic or psychiatric disorders who are incapable of completing the questionnaire. 4.Participants were currently receiving systemic or topical corticosteroids, immunosuppressants, calcineurin inhibitors, biologics (excluding emollients or preservatives), or had received them within 7 days prior to the start of the study. 5.Botulinum toxin injections, dynamic phototherapy or laser therapy administered in the previous six months, or systemic aminoglycoside therapy received within the past two weeks. 6.A medical history of dermatological or other relevant conditions that could potentially impact the accuracy of the test results. 7.The participant must not be currently enrolled in any other clinical trial or have been enrolled within 3 months prior to the start of this study. 8.The individual is currently pregnant, lactating, or has intentions to conceive. 9.Additionally, if the study leader deems it inappropriate to conduct the test.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| IGA75 remission rate (IGA improvement = 75%); | — |
Secondary
| Measure | Time frame |
|---|---|
| Doctor's Global Assessment (PGA);dermatology life quality index; | — |
Countries
China
Contacts
Public ContactYongyong Yuan
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed